Resultados: 9

    Remdesivir for severe COVID-19: a clinical practice guideline

    BMJ; 370 (), 2020
    Clinical question: What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. Aft...

    Coronavirus disease 2019 (COVID-19): The right clinical information, right where it's needed

    A potentially severe acute respiratory infection caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[1] The clinical presentation is generally that of a respiratory infection with a symptom severity ranging from a mild common cold-like illness, to a severe viral ...

    Chinese Guidelines related to Novel Coronavirus Pneumonia

    China has managed to control the coronavirus disease (COVID-19) with confinement measurements and treatment strategies, while other countries are struggling to contain the spread. This study discussesthe guidelines related to COVID-19 in China in order to provide important references for other countries ...

    COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community

    The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice....

    COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community

    The purpose of this guideline is to provide recommendations for managing COVID‑19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection....

    AGA Institute Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic

    Multiple questions have been raised regarding the gastrointestinal and liver manifestations of COVID-19 infection, and implications of SARS-CoV-2 infection on gastrointestinal endoscopy. A joint society statement of the American Gastroenterological Association (AGA), the American Association for the Stud...

    WHO Guidelines for pharmacological management of pandemic Influenza A(H1N1) 2009 and other influenza viruses: part I recommendations

    The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection, as well their use for chemoprophylaxis. This guidance updates and replaces the recommendations published in A...

    WHO Guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses: part II review of evidence

    This revised guidance is published in two parts. Part II documents the procedures followed in developing this guidance, together with a review of evidence and other new information on the pharmacological agents considered....

    Reducing excess mortality from common illnesses during an influenza pandemic WHO guidelines for emergency health interventions in community settings

    Communicable diseases are currently the leading cause of preventable deaths worldwide, disproportionately affecting resource-poor settings. Pandemic influenza would add to already unacceptable levels of morbidity and mortality from diarrhoea, malaria, pneumonia, malnutrition, HIV/AIDS and tuberculosis, i...